Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122730 · ClinicalTrials.gov registry record · Phase 2
VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB
A Phase 2 study, sponsored by Aerogen Pharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03122730 is a Phase 2 study that has completed, run by Aerogen Pharma Limited. The registered enrollment target is 17 participants.
The verdict
NCT03122730, a Phase 2 study, has completed, sponsored by Aerogen Pharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of the Phase 2a study is to: 1) demonstrate that the estimated VentaProst dose is safe and equivalent in effect to a dose administered via epoprostenol aerosolization by the current off-label-use practice; and 2) demonstrate that an optimum effect can be rapidly obtained with VentaProst titration.
Interventions
- COMBINATION_PRODUCT VentaProst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2019-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122730
The ClinicalTrials.gov registry entry for NCT03122730 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerogen Pharma Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VentaProst is the first listed.
NCT03122730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122730 about?
NCT03122730 is a clinical study titled "VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB". The purpose of the Phase 2a study is to: 1) demonstrate that the estimated VentaProst dose is safe and equivalent in effect to a dose administered via epoprostenol aerosolization by the current off-label-use practice; and 2) demonstrate that an optimum effect can be rapidly obtained with VentaProst ...
What is the current status of trial NCT03122730?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2017-08-23. Estimated completion is 2019-05-30.
What interventions are being tested in trial NCT03122730?
The interventions under investigation include: VentaProst (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03122730?
This trial is sponsored by Aerogen Pharma Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.